Clinical trials

Aktualne próby kliniczne, w których nasz Ośrodek bierze aktywny udział:

  • ROSY-O: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib: Dowiedz się więcej
  • PETRA: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies: Dowiedz się więcej
  • SELINA:Prevention of Female Cancers by Optimization of Selenium Levels in the Organism: Dowiedz się więcej
  • SERENA4: A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease: Dowiedz się więcej
  • ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients: Dowiedz się więcej
  • OlympiA: Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer Dowiedz się więcej
  • VIOLETTE: To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy Dowiedz się więcej
  • SOLO-2: Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy Dowiedz się więcej
  • SOLO-1: Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy Dowiedz się więcej
 
Próby kliniczne, w których nasz Ośrodek brał udział:
 
  •  MONO-OLA1: A Randomised, Double-blind, Placebo-controlled, Phase III Study of Olaparib Maintenance Monotherapy in Participants With BRCA Wild Type Advanced High Grade Serous or Endometrioid Ovarian Cancer Following Response to Standard First-line Platinum-based Chemotherapy: Dowiedz się więcej
  • OReO: A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer Dowiedz się więcej
  • SOLO-3: Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments: Dowiedz się więcej
  • LUCY: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients:  Dowiedz się więcej
  • OlympiAD: Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.: Dowiedz się więcej

Clinical trials

Aktualne próby kliniczne, w których nasz Ośrodek bierze aktywny udział:

  • ROSY-O: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib: Dowiedz się więcej
  • PETRA: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies: Dowiedz się więcej
  • SELINA:Prevention of Female Cancers by Optimization of Selenium Levels in the Organism: Dowiedz się więcej
  • SERENA4: A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease: Dowiedz się więcej
  • ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients: Dowiedz się więcej
  • OlympiA: Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer Dowiedz się więcej
  • VIOLETTE: To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy Dowiedz się więcej
  • SOLO-2: Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy Dowiedz się więcej
  • SOLO-1: Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy Dowiedz się więcej
 
Próby kliniczne, w których nasz Ośrodek brał udział:
 
  •  MONO-OLA1: A Randomised, Double-blind, Placebo-controlled, Phase III Study of Olaparib Maintenance Monotherapy in Participants With BRCA Wild Type Advanced High Grade Serous or Endometrioid Ovarian Cancer Following Response to Standard First-line Platinum-based Chemotherapy: Dowiedz się więcej
  • OReO: A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer Dowiedz się więcej
  • SOLO-3: Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments: Dowiedz się więcej
  • LUCY: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients:  Dowiedz się więcej
  • OlympiAD: Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.: Dowiedz się więcej

Clinical trials

Aktualne próby kliniczne, w których nasz Ośrodek bierze aktywny udział:

  • ROSY-O: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib: Dowiedz się więcej
  • PETRA: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies: Dowiedz się więcej
  • SELINA:Prevention of Female Cancers by Optimization of Selenium Levels in the Organism: Dowiedz się więcej
  • SERENA4: A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease: Dowiedz się więcej
  • ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients: Dowiedz się więcej
  • OlympiA: Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer Dowiedz się więcej
  • VIOLETTE: To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy Dowiedz się więcej
  • SOLO-2: Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy Dowiedz się więcej
  • SOLO-1: Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy Dowiedz się więcej
 
Próby kliniczne, w których nasz Ośrodek brał udział:
 
  •  MONO-OLA1: A Randomised, Double-blind, Placebo-controlled, Phase III Study of Olaparib Maintenance Monotherapy in Participants With BRCA Wild Type Advanced High Grade Serous or Endometrioid Ovarian Cancer Following Response to Standard First-line Platinum-based Chemotherapy: Dowiedz się więcej
  • OReO: A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer Dowiedz się więcej
  • SOLO-3: Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments: Dowiedz się więcej
  • LUCY: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients:  Dowiedz się więcej
  • OlympiAD: Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.: Dowiedz się więcej

Do you have any questions?

Contact us and we will dispel all your doubts!

Address

Grzepnica, ul. Alabastrowa 8
72-003 Dobra (Szczecińska)

Phone

Tel: 91 433 42 56
Fax: 91 852 44 33

Email

office@read-gene.com
laboratory@read-gene.com

Read-Gene S.A. © 2021 | Regulamin Strony | Polityka prywatności | Projekt i realizacja: Market Link

Address

Grzepnica, ul. Alabastrowa 8
72-003 Dobra (Szczecińska)

Phone

Tel: 91 433 42 56
Fax: 91 852 44 33

Email

office@read-gene.com
laboratory@read-gene.com

Read-Gene S.A. © 2021 | Regulamin Strony | Polityka prywatności | Projekt i realizacja: Market Link

EN